Status:
UNKNOWN
Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo
Lead Sponsor:
Alexandria University
Conditions:
Vitiligo
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The study to compare the outcomes of mini punch grafting in patients with resistant stable non-segmental vitiligo already on narrowband ultraviolet B and receiving either no additional medication , sy...
Detailed Description
Vitiligo, a depigmenting skin disorder, is characterized by the selective loss of melanocytes, which in turn leads to pigment dilution or loss in the affected areas of the skin. Vitiligo reportedly af...
Eligibility Criteria
Inclusion
- Patients of either gender aged more than 18 years old, with stable resistant non-segmental vitiligo will be included.
- Stability is defined in terms of:
- Absence of new lesions or extension of preexisting lesions prior to presentation for the last 6 months.
- Absence of koebner phenomenon, confetti lesions or hypopigmented lesions, or lesions with ill-defined borders during this same time period.
- Absence of activity signs by dermoscopic examination which includes :
- Ill-defined or trichrome border.
- Micro-Koebner's phenomenon.
- Tapioca sago appearance.
- Starburst appearance.
- Comet tail appearance.
- Altered pigment network. Resistance to treatment is defined in terms of not responding or those responding poorly to administered treatment (\<25% repigmentation according to VASI score) over the last 3 months, especially in patients having lesions on glabrous skin or those with lesions showing leukotrichia.
Exclusion
- Cases of active, the progressive disease having any of the features of activity listed above during the last 6 months.
- Patients with regressive disease showing evidence of repigmentation under administered therapy.
- Patients with segmental vitiligo or vitiligo affecting more than 70% body surface area.
- Patients with associated autoimmune diseases or any other comorbidity. Patients with a tendency towards hypertrophic scars or keloid formation. Pregnant and breast-feeding females. Patients with psychological instability and unrealistic expectations.
Key Trial Info
Start Date :
January 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04765826
Start Date
January 25 2021
End Date
August 1 2022
Last Update
February 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria faculty of medicine
Alexandria, Egypt